Related Experiment Video
Updated: Apr 26, 2026
13:51
Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
9.4K
Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin
Internal Medicine Journal
|July 22, 2014
Summary
Clarithromycin and simvastatin interaction can cause rhabdomyolysis, a serious muscle condition. This case highlights that increased clarithromycin dosage may trigger this adverse event, even affecting cardiac biomarkers.
Area of Science:
- Pharmacology
- Toxicology
- Cardiology
Background:
- Drug interactions involving statins and cytochrome P450 3A4 (CYP3A4) inhibitors are well-documented.
- Clarithromycin is a potent CYP3A4 inhibitor frequently implicated in adverse drug events.
Observation:
- A patient developed rhabdomyolysis, a severe muscle-degeneration condition, following an escalated dose of clarithromycin while on simvastatin therapy.
- The patient exhibited elevated cardiac biomarkers without apparent cardiac pathology, a finding previously associated with rhabdomyolysis.
Findings:
- This case underscores that rhabdomyolysis can manifest or worsen after dose adjustments of interacting medications, specifically clarithromycin.
- The observed troponin elevation in the context of statin-induced rhabdomyolysis suggests a potential link requiring further investigation.
Implications:
- Clinicians must exercise caution when prescribing CYP3A4 inhibitors like clarithromycin concurrently with statins such as simvastatin.
- Awareness of potential myopathy risks and the association between rhabdomyolysis and cardiac biomarker elevation is crucial for patient management.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:30Drug toxicity: Drug–Drug Interaction
422
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
422
01:14Myocarditis III: Medical Management
342
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
342
01:24Nephrotic Syndrome I : Introduction
1.1K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.1K
01:09Hepatic Drug Clearance: Effect of Protein Binding
722
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
722
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
674
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
674